EP2968246A4 - Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation - Google Patents

Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation

Info

Publication number
EP2968246A4
EP2968246A4 EP13878433.5A EP13878433A EP2968246A4 EP 2968246 A4 EP2968246 A4 EP 2968246A4 EP 13878433 A EP13878433 A EP 13878433A EP 2968246 A4 EP2968246 A4 EP 2968246A4
Authority
EP
European Patent Office
Prior art keywords
omega
methods
pentanoic acid
acid compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13878433.5A
Other languages
German (de)
English (en)
Other versions
EP2968246A1 (fr
Inventor
Abdel Aziz Fawzy
George Bobotas
Roelof Rongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Publication of EP2968246A1 publication Critical patent/EP2968246A1/fr
Publication of EP2968246A4 publication Critical patent/EP2968246A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Edible Oils And Fats (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP13878433.5A 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation Withdrawn EP2968246A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/075661 WO2014143272A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation

Publications (2)

Publication Number Publication Date
EP2968246A1 EP2968246A1 (fr) 2016-01-20
EP2968246A4 true EP2968246A4 (fr) 2016-08-03

Family

ID=51537458

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13878433.5A Withdrawn EP2968246A4 (fr) 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation
EP14779339.2A Withdrawn EP2986148A2 (fr) 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14779339.2A Withdrawn EP2986148A2 (fr) 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation

Country Status (4)

Country Link
EP (2) EP2968246A4 (fr)
JP (2) JP2016518315A (fr)
CA (2) CA2905671A1 (fr)
WO (4) WO2014158256A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3233074T3 (pl) 2014-12-15 2023-02-06 Dsm Ip Assets B.V. Leczenie niealkoholowych stłuszczeniowych chorób wątroby
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
EP3456328A4 (fr) * 2016-05-10 2020-02-26 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, et application et préparation pharmaceutique de cette dernière
KR20190113520A (ko) * 2017-02-09 2019-10-08 에스.엘.에이. 파르마 에이지 유리지방산으로서 고도로 정제된 에이코사펜타엔산의 궤양성 대장염 환자의 분변 칼프로텍틴 레벨의 감소 및 임상 재발 방지
CN107006809B (zh) * 2017-04-11 2020-06-09 江南大学 一种有降血脂作用的醋洋葱制品及制备方法
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
PE20250163A1 (es) * 2019-10-25 2025-01-22 Nuseed Nutritional Us Inc Composiciones enriquecidas de acidos grasos poliinsaturados
CN118993893B (zh) * 2024-08-07 2025-06-17 蓝平 一种epa衍生物及其制备方法与用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (fr) * 2005-04-21 2006-10-25 N.V. Nutricia Méthode pour le traitement ou la prévention des insuffisances respiratoires
WO2008032949A1 (fr) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. COMPOSITION À BASE D'HUILE GLYCÉRIDiQUE DÉRIVÉE D'HUILE DE POISSON ET SON PROCÉDÉ DE PRÉPARATION
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (fr) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104856A1 (en) * 2003-05-05 2007-05-10 Hakon Standal Fish oils with an altered fatty acid profile, method of producing same and their use
EP1656839A1 (fr) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition contenant un mélange de lipide
BRPI0516803A (pt) * 2004-11-19 2008-09-23 Martek Biosciences Corp oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
WO2007058523A1 (fr) * 2005-11-17 2007-05-24 N.V. Nutricia Composition comprenant de l'acide docosapentaenoique
KR101383006B1 (ko) * 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
ES2894340T3 (es) * 2009-03-09 2022-02-14 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos y un tensioactivo, y métodos y usos de las mismas
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
WO2011050474A1 (fr) * 2009-10-29 2011-05-05 Acasti Pharma, Inc. Compositions de phospholipides thérapeutiques concentrées
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US8846604B2 (en) * 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (fr) * 2005-04-21 2006-10-25 N.V. Nutricia Méthode pour le traitement ou la prévention des insuffisances respiratoires
WO2008032949A1 (fr) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. COMPOSITION À BASE D'HUILE GLYCÉRIDiQUE DÉRIVÉE D'HUILE DE POISSON ET SON PROCÉDÉ DE PRÉPARATION
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (fr) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014143272A1 *

Also Published As

Publication number Publication date
WO2014143275A1 (fr) 2014-09-18
JP2016518315A (ja) 2016-06-23
WO2014165190A2 (fr) 2014-10-09
CA2905671A1 (fr) 2014-09-18
JP2016512544A (ja) 2016-04-28
CA2905795A1 (fr) 2014-10-09
EP2986148A2 (fr) 2016-02-24
WO2014158256A1 (fr) 2014-10-02
WO2014165190A3 (fr) 2015-01-29
EP2968246A1 (fr) 2016-01-20
WO2014143272A1 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
FR26C1005I1 (fr) Compositions et procédés de modulation de l'expression de l'apolipoprotéine c-iii
FR26C1011I1 (fr) Composés thérapeutiquement actifs et leurs méthodes d'utilisation
EP2861227A4 (fr) Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
EP2964235A4 (fr) Compositions antimicrobiennes-antibiofilm et leurs procédés d'utilisation
IL249821A0 (en) Omega-3 fatty acid ester compositions
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP2968246A4 (fr) Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
EP2841443A4 (fr) Compositions d'arni ciblant serpinc1 et leurs méthodes d'utilisation
EP2915557A4 (fr) Micro-aiguille d'acide rétinoïque
EP3735963C0 (fr) Composition auto-émulsifiante d'acides gras oméga-3
EP2961382A4 (fr) Compositions topiques et leurs procédés d'utilisation
EP2834322A4 (fr) Compositions de biocharbon et leurs procédés d'utilisation
EP2892562A4 (fr) Anticorps anti-mcam et méthodes d'utilisation associées
EP2983661A4 (fr) Formulations d'oxabicycloheptanes et d'oxabicycloheptènes
EP2968280A4 (fr) Triazolopyridines substituées et leurs procédés d'utilisation
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
EP2996694A4 (fr) Compositions de cénicriviroc et leurs procédés de fabrication et d'utilisation
EP3113613A4 (fr) Compositions d'ester de choline de l'acide lipoïque et procédés d'utilisation correspondants
FR3009208B1 (fr) Tete de distribution et d'application
EP2897639A4 (fr) Compositions de vaccins perfectionnées et méthodes d'utilisation
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/232 20060101ALI20160628BHEP

Ipc: A61K 31/202 20060101AFI20160628BHEP

Ipc: A61K 9/48 20060101ALI20160628BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170201